Silencing of CCR2 in myocarditis
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Myocarditis is characterized by inflammatory cell infiltration of the heart and subsequent deterioration of cardiac function. Monocytes are the most prominent population of accumulating leucocytes. We investigated whether in vivo administration of nanoparticle-encapsulated siRNA targeting chemokine (C-C motif) receptor 2 (CCR2)-a chemokine receptor crucial for leucocyte migration in humans and mice--reduces inflammation in autoimmune myocarditis. METHODS AND RESULTS: In myocardium of patients with myocarditis, CCL2 mRNA levels and CCR2(+) cells increased (P < 0.05), motivating us to pursue CCR2 silencing. Flow cytometric analysis showed that siRNA silencing of CCR2 (siCCR2) reduced the number of Ly6C(high) monocytes in hearts of mice with acute autoimmune myocarditis by 69% (P < 0.05), corroborated by histological assessment. The nanoparticle-delivered siRNA was not only active in monocytes but also in bone marrow haematopoietic progenitor cells. Treatment with siCCR2 reduced the migration of bone marrow granulocyte macrophage progenitors into the blood. Cellular magnetic resonance imaging (MRI) after injection of macrophage-avid magnetic nanoparticles detected myocarditis and therapeutic effects of RNAi non-invasively. Mice with acute myocarditis showed enhanced macrophage MRI contrast, which was prevented by siCCR2 (P < 0.05). Follow-up MRI volumetry revealed that siCCR2 treatment improved ejection fraction (P < 0.05 vs. control siRNA-treated mice). CONCLUSION: This study highlights the importance of CCR2 in the pathogenesis of myocarditis. In addition, we show that siCCR2 affects leucocyte progenitor trafficking. The data also point to a novel therapeutic strategy for the treatment of myocarditis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Caforio, A. L. P., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S. B., Fu, M., Heliö, T., Heymans, S., Jahns, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht210 · Cited by 3,479
The many roles of chemokines and chemokine receptors in inflammation
Charo, I. F., & Ransohoff, R. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052723 · Cited by 2,523 · cited 2×
“The chemokine (C-C motif) receptor 2 (CCR2) mediates the egress of inflammatory monocytes from the bone marrow(8) and is essential for recruitment to the site of inflammation.(9) A recent study reported that haematopoietic and myeloid progenitor cells also express CCR2, and that it regulates their migration to inflamm…”
BackgroundIdentification of splenic reservoir monocytes and their deployment to inflammatory sites
Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., Figueiredo, J.-L., Kohler, R. H., Chudnovskiy, A., Waterman, P., et al. (2009) · Science · doi:10.1126/science.1175202 · Cited by 2,221
Self-citationRational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“A spontaneous vesicle formation formulation procedure was performed using disteroylphosphatidyl choline, cholesterol, PEG-DMG, and siRNA.(14,17) The final lipid:siRNA weight ratio was 12:1.”
MethodA Clinical Trial of Immunosuppressive Therapy for Myocarditis
Mason, J. W., O'Connell, J. B., Herskowitz, A., Rose, N. R., McManus, B. M., Billingham, M. E., & Moon, T. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330501 · Cited by 1,274 · cited 2×
“The high variability of the clinical manifestations and aetiology of myocarditis(27) may explain why several clinical trials of immunosuppression for acute myocarditis have shown negative results.(4,28) An al-”
BackgroundCooper, L. T., Baughman, K. L., Feldman, A. M., Frustaci, A., Jessup, M., Kuhl, U., Levine, G. N., Narula, J., Starling, R. C., Towbin, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.186093 · Cited by 1,030
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969 · cited 2×
“Briefly, nanoparticle siRNA formulations were prepared using the lipid C12-200.(13) A spontaneous vesicle formation formulation procedure was performed using disteroylphosphatidyl choline, cholesterol, PEG-DMG, and siRNA.”
MethodSelf-citationTherapeutic siRNA silencing in inflammatory monocytes in mice
Leuschner, F., Dutta, P., Gorbatov, R., Novobrantseva, T. I., Donahoe, J. S., Courties, G., Lee, K. M., Kim, J. I., Markmann, J. F., Marinelli, B., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1989 · Cited by 839 · cited 2×
“siRNA targeting CCR2 was synthesized and encapsulated into lipidoid nanoparticles (LNPs), as described previously.(12) Briefly, nanoparticle siRNA formulations were prepared using the lipid C12-200.”
BackgroundMethodSelf-citationSagar, S., Liu, P. P., & Cooper, L. T. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60648-x · Cited by 743
Chapter 4 Pathogenesis of Myocarditis and Dilated Cardiomyopathy
Cihakova, D., & Rose, N. R. (2008) · Advances in Immunology · doi:10.1016/s0065-2776(08)00604-4 · Cited by 223
Cited by
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Myocarditis and inflammatory cardiomyopathy: current evidence and future directions
Tschöpe, C., Ammirati, E., Bozkurt, B., Caforio, A. L. P., Cooper, L. T., Felix, S. B., Hare, J. M., Heidecker, B., Heymans, S., Hübner, N., et al. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00435-x · Cited by 1,217
Chronic Heart Failure and Inflammation: What Do We Really Know?
Dick, S. A., & Epelman, S. (2016) · Circulation Research · doi:10.1161/circresaha.116.308030 · Cited by 692
Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure
Koenig, A. L., Shchukina, I., Amrute, J., Andhey, P. S., Zaitsev, K., Lai, L., Bajpai, G., Bredemeyer, A., Smith, G., Jones, C., et al. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00028-6 · Cited by 482
Metadata
- Authors
- Leuschner, F., Courties, G., Dutta, P., Mortensen, L. J., Gorbatov, R., Sena, B., Novobrantseva, T. I., Borodovsky, A., Fitzgerald, K., Koteliansky, V., Iwamoto, Y., Bohlender, M., Meyer, S., Lasitschka, F., Meder, B., Katus, H. A., Lin, C., Libby, P., Swirski, F. K., Anderson, D. G., Weissleder, R., & Nahrendorf, M.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-20
- Volume
- 36
- Issue
- 23
- Pages
- 1478-1488
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2163857843
- Cited by
- 149
- References
- 12
- FWCI
- 4.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Silencing of CCR2 in myocarditis. https://app.cochat.ai/papers/10.1093/eurheartj/ehu225
- The paper
- Leuschner, F., Courties, G., Dutta, P., Mortensen, L. J., Gorbatov, R., Sena, B., Novobrantseva, T. I., Borodovsky, A., Fitzgerald, K., Koteliansky, V., Iwamoto, Y., Bohlender, M., Meyer, S., Lasitschka, F., Meder, B., Katus, H. A., Lin, C., Libby, P., Swirski, F. K., . . . Nahrendorf, M. (2015). Silencing of CCR2 in myocarditis. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.